Systems and methods for evaluating glymphatic health and function using EEG and nirs
A combined EEG and NIRS system monitors glymphatic function during sleep, addressing the lack of real-time visualization tools by quantifying cerebral water fraction changes and neurovascular coupling, enhancing brain health assessment and therapeutic strategies for neurodegenerative disorders.
Patent Information
- Application Number
- PCT/US2026/027167
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Current technologies lack effective tools for real-time visualization and feedback on glymphatic system activity, which is crucial for understanding brain health and potential neurodegenerative disorders, as dysfunction in the glymphatic system precedes or predisposes individuals to protein accumulations.
A system combining electroencephalography (EEG) sensors and near-infrared spectroscopy (NIRS) sensors is used to monitor glymphatic cerebrospinal fluid and hemoglobin fluctuations during sleep, processing data to determine metrics such as sleep efficacy, entrainment of neural activity into hemodynamic signals, and neurovascular coupling, providing a wearable and wireless monitoring solution.
Enables real-time monitoring of glymphatic function, offering insights into brain health and potential therapeutic strategies for neurodegenerative diseases by quantifying cerebral water fraction changes and neurovascular dynamics.
Smart Images

Figure US2026027167_12112026_PF_FP_ABST
Abstract
Description
Atty.Dkt.No. 125141.05018.MGH2025-378SYSTEMS AND METHODS FOR EVALUATING GLYMPHATIC HEALTH AND FUNCTION USING EEG AND NIRSCROSS-REFERENCE TO RELATED APPLICATION(S)
[0001] This application claims priority- to U.S. Provisional Patent Application Serial No.63 / 801,700, titled '‘System for and Method of Evaluating Glymphatic Health and Function Using EEG and NIRS” and fded May 7, 2025, the content of which is hereby incorporated by reference in its entirety .STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0002] This invention was made with government support under award number AU2AX000007 (agreement 2024A014963) from the Advanced Research Projects Agency for Health. The government has certain rights in the invention.BACKGROUND
[0003] The glymphatic system (GS) is a neural pathway that plays a role in the removal of cerebral waste and toxins from the central nervous system. The glymphatic system comprises a network of perivascular channels alongside cerebral blood vessels and demonstrates activity during sleep.SUMMARY
[0004] This summary is provided to introduce a selection of concepts in a simplified form that are further described below in the detailed description. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.
[0005] In some aspects, a system for evaluating brain health of a subject is provided. The system includes a sensor assembly comprising one or more electroencephalography (EEG) sensors and a plurality- of near-infrared spectroscopy (NIRS) sensors including a light source and a photodetector. The system further includes a control unit in electrical communication with the sensor assembly. The control unit can be configured to acquire, via the sensor assembly, EEG data from the EEG sensors and NIRS data from the NIRS sensors, the EEG data and NIRS data obtained during a sleeping state of the subject. The control unit can beAtty.Dkt.No. 125141.05018.MGH2025-378configured to process the EEG data and NIRS data to identify a first plurality of oscillations in the EEG data and a second plurality of oscillations in the NIRS data. The control unit can be configured to determine a metric based on the first plurality of oscillations and the second plurality of oscillations. The control unit can be configured to output a report to a user, the report indicating a predicted brain health of the subject based on the metric.
[0006] In some examples, the metric may be determined based on an area under a curve of the second plurality of oscillations, wherein the metric corresponds to a predicted sleep efficacy.
[0007] In some examples, the metric may be determined by comparing a spectral power of the first plurality of oscillations and the second plurality of oscillations at various sleep stages, wherein the metric corresponds to an entrainment of low-frequency neural activity into hemodynamic signals.
[0008] In some examples, the spectral power may correspond to frequency bands of approximately 0.01 Hz to 0.15 Hz.
[0009] In some examples, the metric may be determined based on a timing delay between the first plurality of oscillations and the second plurality of oscillations, wherein the metric corresponds to neurovascular coupling.
[0010] In some examples, the timing delay may be between 4 seconds and 6 seconds between a peak of neural activity and a peak of a hemodynamic response.
[0011] In some examples, the control unit may be further configured to determine a first metric based on an area under a curve of the second plurality of oscillations, wherein the first metric corresponds to a predicted sleep efficacy. The control unit may be further configured to determine a second metric by comparing a spectral power of the first plurality of oscillations and the second plurality of oscillations at various sleep stages, wherein the second metric corresponds to an entrainment of low-frequency neural activity into hemodynamic signals. The control unit may be further configured to determine a third metric based on a timing delay between the first plurality of oscillations and the second plurality of oscillations, wherein the third metric corresponds to neurovascular coupling.
[0012] In some examples, the sensor assembly may be wearable.
[0013] In some examples, the first plurality of oscillations may comprise low frequency hemodynamic oscillations driven by infraslow oscillations of approximately 0.05 Hz of delta EEG power.Atty.Dkt.No. 125141.05018.MGH2025-378
[0014] In some examples, the control unit may be further configured to acquire, via the plurality of NIRS sensors, a plurality of wavelengths around a water absorption peak and identify cerebral water fraction changes from the plurality of wavelengths.
[0015] In some aspects, a method for evaluating brain health of a subject is provided. The method includes acquiring, via a sensor assembly comprising one or more electroencephalography (EEG) sensors and a plurality of near-infrared spectroscopy (NIRS) sensors, EEG data and NIRS data during a sleeping state of the subject. The method includes pre-processing the EEG data and NIRS data to identify a first plurality of oscillations in the EEG data and a second plurality of oscillations in the NIRS data. The method includes determining a metric based on the first plurality of oscillations and the second plurality of oscillations. The method includes outputting a report to a user, the report indicating a predicted brain health of the subject based on the metric.
[0016] In some examples, the metric may be determined based on an area under a curve of the second plurality of oscillations, wherein the metric corresponds to a predicted sleep efficacy.
[0017] In some examples, the metric may be determined by comparing a spectral power of the first plurality of oscillations and the second plurality of oscillations at various sleep stages, wherein the metric corresponds to an entrainment of low-frequency neural activity' into hemodynamic signals.
[0018] In some examples, the spectral power may correspond to frequency’ bands of approximately 0.01 Hz to 0.15 Hz.
[0019] In some examples, the metric may be determined based on a timing delay between the first plurality' of oscillations and the second plurality' of oscillations, wherein the metric corresponds to neurovascular coupling.
[0020] In some examples, the timing delay may be between 4 seconds and 6 seconds between a peak of neural activity and a peak of a hemodynamic response.
[0021] In some examples, the method may further include determining a first metric based on an area under a curve of the second plurality of oscillations, wherein the first metric corresponds to a predicted sleep efficacy. The method may further include determining a second metric by comparing a spectral power of the first plurality of oscillations and the second plurality' of oscillations at various sleep stages, wherein the second metric corresponds to an entrainment of low-frequency neural activity' into hemodynamic signals. The method may further include determining a third metric based on a timing delay between the first pluralityAtty.Dkt.No. 125141.05018.MGH2025-378of oscillations and the second plurality of oscillations, wherein the third metric corresponds to neurovascular coupling.
[0022] In some examples, the sensor assembly may be wearable.
[0023] In some examples, the second plurality of oscillations may comprise low frequency hemodynamic oscillations driven by infraslow oscillations of approximately 0.05 Hz of delta EEG power.
[0024] In some examples, the method may further include acquiring, via the plurality of NIRS sensors, a plurality of wavelengths around a water absorption peak and identifying cerebral water fraction changes from the plurality of wavelengths.
[0025] The foregoing general description of the illustrative embodiments and the following detailed description thereof are merely exemplary aspects of the teachings of this disclosure and are not restrictive.BRIEF DESCRIPTION OF THE DRAWINGS
[0026] FIG. 1 illustrates an example monitoring system for evaluating glymphatic health and function, according to aspects of the present disclosure.
[0027] FIG. 2 illustrates an example system for evaluating glymphatic health and function, according to aspects of the present disclosure.
[0028] FIG. 3 illustrates an example sensor assembly comprising an electroencephalography (EEG) montage and a near-infrared spectroscopy (NIRS) portion, according to aspects of the present disclosure.
[0029] FIG. 4 illustrates an exploded view of a sensor assembly, according to aspects of the present disclosure.
[0030] FIG. 5 illustrates a flowchart for a process for evaluating glymphatic health and function, according to aspects of the present disclosure.
[0031] FIG. 6 illustrates a flow diagram depicting a relationship between neuronal slow waves, blood volume oscillations, and cerebrospinal fluid flow, according to aspects of the present disclosure.
[0032] FIG. 7A illustrates an example plot of slow-delta EEG, according to aspects of the present disclosure.
[0033] FIG. 7B illustrates an example plot of d / dt blood-oxygen-level-dependent (BOLD), according to aspects of the present disclosure.
[0034] FIG. 7C illustrates an example plot of cerebrospinal fluid (CSF) signal, according to aspects of the present disclosure.Atty.Dkt.No. 125141.05018.MGH2025-378
[0035] FIG. 8 illustrates example plots showing low frequency oscillation power during sleep, according to aspects of the present disclosure.
[0036] FIG. 9A illustrates an example EEG power spectral density plot across different sleep stages, according to aspects of the present disclosure.
[0037] FIG. 9B illustrates an example NIRS power spectral density' plot across different sleep stages, according to aspects of the present disclosure.
[0038] FIG. I0A illustrates an example N3 sleep stage delta-band power plot, according to aspects of the present disclosure.
[0039] FIG. 10B illustrates an example REM sleep stage delta-band power plot, according to aspects of the present disclosure.
[0040] FIG. 10C illustrates an example N3 sleep stage hemoglobin concentration plot, according to aspects of the present disclosure.
[0041] FIG. 10D illustrates an example REM sleep stage hemoglobin concentration plot, according to aspects of the present disclosure.
[0042] FIG. 11 A illustrates an example fMRI timeseries plot during yvakefulness, according to aspects of the present disclosure.
[0043] FIG. 11B illustrates an example fMRI timeseries plot during sleep, according to aspects of the present disclosure.
[0044] FIG. 11C illustrates an example timeseries plot during wake, according to aspects of the present disclosure.
[0045] FIG. 11D illustrates an example timeseries plot during deep sleep, according to aspects of the present disclosure.
[0046] FIG. 12A illustrates an example plot of overnight hemoglobin and water fraction concentrations, according to aspects of the present disclosure.
[0047] FIG. 12B illustrates an example plot of accelerometer output during overnight measurement, according to aspects of the present disclosure.
[0048] FIG. 12C illustrates an example plot of sleep staging during overnight measurement, according to aspects of the present disclosure.
[0049] FIG. 13 A illustrates an example plot of changes in oxy-hemoglobin concentration during deep sleep, according to aspects of the present disclosure.
[0050] FIG. 13B illustrates an example plot of changes in deoxy -hemoglobin concentration during deep sleep, according to aspects of the present disclosure.
[0051] FIG. 13C illustrates an example plot of changes in water fraction during deep sleep, according to aspects of the present disclosure.Atty.Dkt.No. 125141.05018.MGH2025-378
[0052] FIG. 14A illustrates example plots of estimated recovery' of chromophore changes using Monte Carlo simulation, according to aspects of the present disclosure.
[0053] FIG. 14B illustrates example data collected with a modified FlexNIRS device, according to aspects of the present disclosure.
[0054] FIG. 15 illustrates example plots of low frequency oscillation analysis during sleep, according to aspects of the present disclosure.DETAILED DESCRIPTION
[0055] The detailed description set forth below in connection with the appended drawings is intended as a description of various configurations and is not intended to represent the only configurations in which the subject matter described herein may be practiced. The detailed description includes specific details to provide a thorough understanding of various embodiments of the present disclosure. However, it will be apparent to those skilled in the art that the various features, concepts, and embodiments described herein may be implemented and practiced without these specific details. In some instances, well-known structures and components are shown in block diagram form to avoid obscuring such concepts.
[0056] Aspects of the present disclosure relate to systems and methods for evaluating glymphatic health and function using near-infrared spectroscopy (NIRS) in combination with electroencephalography (EEG). NIRS is a noninvasive diffuse optical technique that employs light at various wavelengths to discern absorption changes of tissue chromophores, including hemoglobin, lipid, and water. In accordance with aspects of the present disclosure, NIRS may be utilized to detect an increase in low-frequency hemoglobin concentration oscillations during deep sleep, which may be consistent with blood-oxygen-level-dependent (BOLD) MRI oscillations observed during glymphatic system activity. In some embodiments, a wearable, wireless NIRS device may be employed to monitor glymphatic cerebrospinal fluid (CSF) and hemoglobin fluctuations during naturalistic sleep. In certain embodiments, the NIRS device may include wavelengths around the water absorption peak to resolve cerebral water fraction changes associated with glymphatic function.
[0057] The glymphatic system (GS) is a component of the brain's waste clearance mechanism, playing a role in the removal of metabolic waste and toxins, including amyloid- / ? and tau proteins implicated in the pathogenesis of Alzheimer's disease and other neurodegenerative disorders. Active during the slow-wave sleep stage, the GS operates as a network of perivascular channels that facilitate the exchange of cerebrospinal fluid (CSF) and interstitial fluid (ISF). This system eliminates neurotoxic byproducts, underscoring its significance inAtty.Dkt.No. 125141.05018.MGH2025-378maintaining brain health. Dysfunction in the GS may precede or predispose individuals to protein accumulations in neurodegenerative diseases, emphasizing the importance of understanding the dynamics of the GS and its connection to cognitive decline. Various approaches may be employed to enhance glymphatic function, including vagal nerve stimulation, acupuncture, maintaining adequate sleep, regular physical exercise, and a balanced diet, showing potential for therapeutic strategies aimed at addressing neurodegenerative diseases and other neurological disorders. These considerations highlight the need for tools capable of visualizing glymphatic system activity in real-time, providing an avenue for feedback on strategies aimed at preserving brain health. GS activity may be manifested as an expansion of the interstitial space. GS activity may be further characterized by convective exchange of CSF and ISF driven by cerebrovascular oscillations that span cardiac, respiratory, and lower frequencies. These oscillations may drive fluid into the perivascular space, enabling clearance and exchange of ISF, and their disruption or irregularities may be associated with imbalances in ISF dynamics. Electroencephalography (EEG) may provide insights into neuronal influences of glymphatic activity, revealing that brain-wide oscillations evident in delta frequency power during deep sleep may be associated with an enhanced glymphatic clearance process. CSF oscillations, slow hemoglobin oscillations, and EEG delta activity may be correlated, highlighting the interplay between vascular dynamics and neural activity in the context of glymphatic function. These considerations demonstrate the significance of comprehending how cerebral water fraction volume and oscillatory dynamics changes, cerebral hemodynamic fluctuations, and neuronal activity collectively influence waste clearance, thereby presenting opportunities for GS monitoring in the context of cognitive health and neurodegenerative disorders.
[0058] Referring to FIG. 1, an example monitoring system 100 that can be used to evaluate glymphatic health and function is illustrated. In the monitoring system 100, a subject 104 (such as a medical patient) is monitored using one or more inputs, such as a sensor assembly 106, each of which transmits a signal over a cable 108 or other communication link or medium to an EEG and NIRS monitor 120. In some aspects, an input (not shown) may be configured to receive an indication from a user. The EEG and NIRS monitor 120 includes a processor 112 and, optionally, a display 102. The sensor assembly 106 includes one or more electroencephalography (EEG) sensors (e.g., electrodes, bipolar electrodes, etc.) configured to measure cerebral electrical activity and one or more near-infrared spectroscopy (NIRS) sensors (e.g., light sources and corresponding light detectors) configured to measure cerebral hemodynamics. The sensor assembly 106 can generate respective signals by measuringAtty.Dkt.No. 125141.05018.MGH2025-378physiological parameters of the subject 104. The signals are then processed by one or more processors 112. In some embodiments, the one or more processors 112 can be any suitable hardware processor or combination of processors, such as a central processing unit (CPU), a graphics processing unit (GPU), and so on. The one or more processors 112 then communicate the processed signal to the display 102, if a display 102 is provided. In some embodiments, display 102 can include any suitable display devices, such as a liquid crystal display (LCD) screen, a light-emitting diode (LED) display, an organic LED (OLED) display, an electrophoretic display (e.g., an “e-ink” display), a computer monitor, a touchscreen, a television, and so on. In an embodiment, the display 102 is incorporated in the EEG and NIRS monitor 120. In another embodiment, the display 102 is separate from the EEG and NIRS monitor 120. The monitoring system 100 is a portable monitoring system in one configuration. In another instance, the brain monitoring system 100 is a pod, without a display, and is adapted to provide physiological parameter data to a display.
[0059] For clarity7, a single block is used to illustrate the sensor assembly 106 shown in FIG. 1. It should be understood that the sensor assembly 106 shown is intended to represent one or more sensors and adapted to receive signals from the subject 104. For example, the sensor assembly 106 can include one or more EEG sensors configured to measure cerebral electrical activity, one or more NIRS sensors configured to measure cerebral hemodynamics, and other sensors used for other physiological recordings. Various combinations of numbers and types of sensors, as mentioned, are suitable for use with the brain monitoring system 100.
[0060] In some embodiments of the system show n in FIG. 1, all of the hardw are used to receive and process signals from the sensors are housed within the same housing. In other embodiments, some of the hardware used to receive and process signals is housed w ithin a separate housing. In addition, the EEG and NIRS monitor 120 of certain embodiments includes hardware, software, or both hardware and software, whether in one housing or multiple housings, used to receive and process the signals transmitted by the sensor assembly 106.
[0061] Referring to FIG. 2, an example system 200 for use in carrying out steps in accordance with the present disclosure, is illustrated. The system 200 may include an input 202, a pre-processor 204, a glymphatic function analysis engine 206, and an output 208. Some or all of the modules of the system 100 can be implemented by a EEG and NIRS monitor as described above with respect to FIG. 1.
[0062] The input 202 may be configured to accept an indication from a user related to a particular subject profile such as a subject's age, height, weight, gender, or the like, as well as sleep-related parameters or clinical history7relevant to glymphatic function assessment.Atty.Dkt.No. 125141.05018.MGH2025-378
[0063] The pre-processor 204 may be designed to carry' out any number of processing steps for operation of system 200. In particular, the pre-processor 204 may be configured to receive EEG and NIRS data obtained via input 202 and process the data. Additionally, the preprocessor 204 may be capable of performing steps for removing interfering and / or undesired signals associated with the data via signal rejection or filtering techniques. In some aspects, the pre-processor 204 may utilize systemic physiology regression to ensure hemodynamic signals truly reflect cerebral physiology. In some aspects, the pre-processor 204 may also be configured to assemble raw or processed signals from acquired physiological data into timefrequency representations such as telemetry' traces. For instance, the pre-processor 204 may process and assemble acquired EEG and NIRS data, for example, to identify low-frequency hemodynamic oscillations and infraslow oscillations in delta band EEG power in the data. In some aspects, the pre-processor 204 may also be configured to receive an indication from a user and perform pre-processing steps in accordance with the indication.
[0064] In addition to the pre-processor 204, the system 200 further includes the glymphatic function analysis engine 206, in communication with the pre-processor 204. designed to receive pre-processed data from the pre-processor 204 and carry out steps for evaluating glymphatic health and function. The glymphatic function analysis engine 206 may be configured to compute one or more metrics indicative of glymphatic system activity7. In some aspects, the glymphatic function analysis engine 206 may compute a first metric based on a total dose of low frequency7hemodynamic oscillation measured throughout a sleep period. The low frequency oscillations may be driven by infraslow oscillations (approximately 0.05 Hz) of delta (0.5 to 4.0 Hz) EEG power, and by summing the area under the curve of the low frequency hemodynamic oscillations, the glymphatic function analysis engine 206 may compute a dose metric that can predict sleep efficacy. In some aspects, the glymphatic function analysis engine 206 may compute a second metric derived by comparing spectral power in low frequency bands (0.01 to 0.15 Hz) of the hemodynamic signals during different sleep stages as measured by EEG. The contrast or lack of contrast in the low frequency power between different sleep stages may be indicative of proper or improper entrainment of the low frequency neural activity into the hemodynamic signals. In some aspects, the glymphatic function analysis engine 206 may compute a third metric based on timing of the infraslow oscillations in the delta band EEG power and the oscillations in the hemodynamic signals. For neurovascular coupling, a delay of approximately 4-6 seconds between the peak of neural activity and the peak of the hemodynamic response may be observed. The degree of neurovascular coupling as observedAtty.Dkt.No. 125141.05018.MGH2025-378through this timing metric, combined with the sleep stage when the signals were measured, may be indicative of the level of activity of the glymphatic system.
[0065] An output 208 of the system 200 may be configured to present results of the glymphatic function analysis to a user or to transmit the results to another system or device. In some aspects, the output 208 may include a display configured to render a visual representation of the computed metrics, such as graphical depictions of the dose metric, sleep stage contrast metric, or neurovascular coupling timing metric. The output 208 may also be configured to generate alerts or notifications when computed metrics fall outside of predetermined thresholds indicative of impaired glymphatic function. In some aspects, the output 208 may provide a summary report including one or more of the computed metrics along with trend data over multiple sleep sessions, enabling longitudinal tracking of glymphatic health.
[0066] In some embodiments, the output 208 may be configured to transmit data to external systems, such as electronic health record systems, remote monitoring platforms, or cloud-based storage systems. The output 208 may also be configured to provide data in formats suitable for further analysis by clinicians or researchers. In some aspects, the output 208 may include an interface for exporting raw or processed data, computed metrics, or both, to facilitate integration with other diagnostic or therapeutic systems.
[0067] Referring to FIG. 3, an example embodiment of a sensor assembly 300 (such as sensor assembly 106) is illustrated. The sensor assembly 300 is a wearable electroencephalography and near-infrared spectroscopy instrument configured to permit measurements of cerebral electrical activity and cerebral hemodynamics. In some embodiments, the sensor assembly 300 may be designed for comfortable, extended wear during sleep periods to facilitate naturalistic monitoring of glymphatic function. The sensor assembly 300 can include an EEG montage 302 and aNIRS portion 304. The EEG montage 302 may include a plurality of electrodes positioned according to standard or modified electrode placement configurations to capture cerebral electrical activity across multiple brain regions. The NIRS portion 304 may include one or more light sources and detectors configured to measure changes in cerebral hemoglobin concentrations and, in some embodiments, cerebral water fraction changes associated with glymphatic function.
[0068] Referring to FIG. 4, another example embodiment of a sensor assembly 400 (such as sensor assembly 106 or the NIRS portion 304 of the sensor assembly 300) is illustrated. FIG.4 illustrates a skin view 402, a top view 404, and an encased view 406 of the sensor assembly 400. The skin view 402 depicts the surface of the sensor assembly 400 that contacts the subject's skin during use. The top view 404 illustrates the external surface of the sensor assembly 400Atty.Dkt.No. 125141.05018.MGH2025-378opposite the skin-contacting surface. As illustrated in the encased view 406, in some examples, the sensor assembly 400 may be encased with a silicone elastomer. The silicone elastomer encasement may provide protection for the internal components of the sensor assembly 400 while maintaining flexibility and comfort for the wearer during extended monitoring periods.
[0069] The sensor assembly 400 can include an optical sensor portion 408 and a communication portion 410. The optical sensor portion 408 may include one or more light sources configured to emit near-infrared light at various wavelengths and one or more detectors configured to receive light that has passed through or been reflected by cerebral tissue. In some embodiments, the optical sensor portion 408 may include wavelengths around the water absorption peak to resolve cerebral water fraction changes associated with glymphatic function. The communication portion 410 may not contact the surface of the subject's skin. The communication portion 410 can include an analog front end (AFE) and Bluetooth Low Energy (BLE) circuitry to wirelessly communicate to a connected tablet, smartphone, or other device. This wireless communication capability enables the sensor assembly 400 to transmit acquired EEG and NIRS data to external processing devices without requiring wired connections that may interfere with naturalistic sleep monitoring. The sensor assembly 400 can further include a rechargeable battery 412. The rechargeable battery 412 may be configured to provide power for monitoring sessions, such as overnight sleep studies, without requiring external power connections.
[0070] In some aspects, the NIRS portion 304 of the sensor assembly 300 and / or the sensor assembly 400 may be configured to detect CSF signals by measuring cerebral water fraction. In particular, because CSF is primarily composed of water, changes in cerebral water fraction detected at wavelengths near the water absorption peak (e.g., 970 nm) may correspond to CSF volume changes and oscillations. This may enable detection of low-frequency CSF oscillations associated with glymphatic activity during sleep. In some examples, the water fraction measurements may serve as a proxy for monitoring CSF dynamics, including CSF flow and level changes in interstitial and perivascular volume.
[0071] Turning to FIG. 5, a process 500 in accordance with the present disclosure is illustrated. As described below, a particular implementation can omit some or all illustrated features / steps, may be implemented in some embodiments in a different order, and may not require some illustrated features to be implemented in all embodiments. In some examples, an apparatus (e.g., computing device, processor with memory', a monitor, etc.) can be used to perform example process 500. However, it should be appreciated that any suitable apparatus or system for carrying out the operations or features described below may perform process 500.Atfy.Dkt.No. 125141.05018.MGH2025-378
[0072] At operation 505, CSF volume is acquired during a sleeping state of a subject. In some embodiments, the CSF volume may be acquired using the sensor assembly 106 of the monitoring system 100 described with respect to FIG. 1. The sensor assembly 106 may include one or more NIRS sensors configured to measure cerebral hemodynamics, including CSF volume changes associated with glymphatic function. In some aspects, the NIRS sensors may include wavelengths around the water absorption peak to resolve cerebral water fraction changes, as described with respect to the sensor assembly 300 of FIG. 3 and the optical sensor portion 408 of the sensor assembly 400 of FIG. 4.
[0073] At operation 510, EEG data and NIRS data is acquired during the sleeping state of the subject. In some embodiments, the EEG data may be acquired using the one or more EEG sensors of the sensor assembly 106. which are configured to measure cerebral electrical activity. As described with respect to FIG. 3, the sensor assembly 300 may include an EEG montage 302 comprising a plurality of electrodes positioned according to standard or modified electrode placement configurations to capture cerebral electrical activity7across multiple brain regions. The NIRS data may be acquired concurrently using the NIRS portion 304 of the sensor assembly 300 or the optical sensor portion 408 of the sensor assembly 400, which include one or more light sources and detectors configured to measure changes in cerebral hemoglobin concentrations.
[0074] At operation 515, low-frequency EEG oscillations in the EEG data and the NIRS data are identified. In some embodiments, the pre-processor 204 may process and assemble the acquired EEG and NIRS data to identify hemodynamic oscillations and infraslow oscillations in delta band EEG power. For example, the hemodynamic oscillations may be low frequency oscillations driver by infraslow oscillations of delta EEG power. In some examples, oscillations may be identified using a filter (e.g., a bandpass filter, a low pass filter, etc.) on the NIRS signal. For example, a bandpass filter can extract oscillations within a frequency range between about 0.01 Hz to about 0.15 Hz. In some cases, the low' pass filter can have a cutoff frequency at or below7about 0.015 Hz. The NIRS signal may be an NIRS intensify, an NIRS optical densify signal (e.g., the changes in optical densify), or an NIRS-derived concentration of tissue chromophores. As described below, in some embodiments, the EEG and the NIRS data may be used independently to determine certain metrics, while in other embodiments, the EEG data and the NIRS data may be combined to determine certain metrics. FIG. 6 illustrates a flow7diagram 600 of oscillations extracted from the EEG data and the NIRS data. The oscillations may include neuronal slow waves or slow delta waves 602 and blood volume oscillations 604. As illustrated in FIG. 6, example CSF flow' oscillations 606 may be identified from the CSFAtty.Dkt.No. 125141.05018.MGH2025-378volume data obtained at operation 505. FIGS. 7A, 7B, and 7C illustrate example plots 710, 720, 730 of slow delta wave, blood volume low frequency oscillation (LFO), and CSF LFO, respectively. As illustrated by plots 710, 720, 730, during slow wave sleep, temporal coupling between delta EEG power, blood volume (d / dt blood oxygen level-dependent (BOLD)), and CSF flow were measured.
[0075] Referring to FIG. 8. two example plots 810, 820 illustrating low frequency oscillation (LFO) power dunng sleep are shown. The plots 810, 820 illustrate that the longer a subject spends in sleep with higher low frequency activi ty in the hemodynamic signals, the greater the clearance activity of the glymphatic system may be. The LFO high-power periods in the plots 810, 820 may be quantified to assess glymphatic function. The first plot 810 illustrates that longer high-power periods may correspond to higher glymphatic system clearance. The second plot 820 illustrates NIRS low frequency power in the AHbT signal measured during a full night of sleep with a previous generation FlexNIRS device.
[0076] At operation 520, a first metric is determined, which corresponds to a predicted sleep efficacy of the subject. In some embodiments, the first metric may be computed by the glymphatic function analysis engine 206 based on pre-processed data received from the preprocessor 204. In some examples, the first metric may use (e.g., only use) time series of the NIRS data. In some aspects, low-frequency power over time (e.g., the power of the low frequency components over time, such as those extracted using a filter) may be computed using a short time Fourier transform method, such as a multi -taper spectrogram. The first metric may be based on a total dose of low frequency hemodynamic oscillation measured throughout a sleep period. The low frequency oscillations may be driven by infraslow oscillations (approximately 0.05 Hz) of delta (0.5 to 4.0 Hz) EEG power. By summing the area under the curve of the low frequency hemodynamic oscillations, the glymphatic function analysis engine 206 may compute a dose metric that can predict sleep efficacy.
[0077] At operation 525, a second metric is determined, which corresponds to an entrainment of low-frequency neural activity into hemodynamic signals. In some embodiments, the second metric may be computed by the glymphatic function analysis engine 206 based on pre-processed data received from the pre-processor 204. In some examples, the second metric may use the EEG data for sleep stage determination (e.g., determine a sleep stage from the EEG data). Moreover, in some aspects, low frequency power in the NIRS time series may be computed as a function of the sleep stage as determined from the EEG data (e.g., the NIRS time series can be tied to a particular identified sleep stage). The second metric may be derived by comparing the spectral power in the low frequency bands (0.01 to 0.15 Hz) of theAtty.Dkt.No. 125141.05018.MGH2025-378hemodynamic signals during different sleep stages as measured by EEG. The contrast or lack of contrast in the low frequency power between different sleep stages may be indicative of proper or improper entrainment of the low frequency neural activity into the hemodynamic signals. Infraslow oscillations (approximately 0.05 Hz) in EEG delta waves during sleep may trigger an entrainment of neurovascular coupling at the slow oscillation frequency . This may¬ cause blood volume oscillations and may drive bulk CSF motion inside the skull. The volume oscillations may provide a pressure gradient to push fluid across the blood brain barner to clear waste products that accumulate during periods of wakefulness. In some aspects, the preprocessor 204 may utilize systemic physiology- regression to ensure hemodynamic signals truly reflect cerebral physiology when computing the second metric, as well as the first metric and the third metric.
[0078] Referring to FIGS. 9A and 9B, two example plots 910, 920 corresponding to EEG and NIRS data are illustrated. During deep stages of sleep (N2, N3), low frequency oscillations are more prominent in both EEG and NIRS. In some embodiments, the glymphatic function analysis engine 206 may analyze relative power in the low frequency band generally (0.01 to 0.15 Hz) or at approximately 0.05 Hz, across sleep stages as a biomarker for glymphatic health. The contrast in low frequency power between different sleep stages, as illustrated in FIGS. 9A and 9B, may be indicative of proper or improper entrainment of low frequency neural activity into hemodynamic signals, which may correspond to the second metric computed by the glymphatic function analysis engine 206 as described above with respect to operation 525.
[0079] At operation 530, a third metric is determined, which corresponds to neurovascular coupling. In some embodiments, the third metric may be computed by the glymphatic function analysis engine 206 based on pre-processed data received from the pre-processor 204. In some examples, the third metric may use the power in the EEG delta frequency band as a time signal. Moreover, in some aspects, a cross correlation between the summed EEG delta power and the NIRS optical signals may be computed to assess the strength and lag of the relationship between the parameters. The NIRS optical signals may include an NIRS intensity, a change in optical density, or a concentration of tissue chromophores. The cross correlation may be computed across a sleep period, as well as a function of sleep stages (e.g., across sleep stages). The third metric may be based on the timing of the infraslow oscillations in the delta band EEG power and the oscillations in the hemodynamic signals. For neurovascular coupling, a delay of approximately 4-6 seconds between the peak of neural activity and the peak of the hemodynamic response may be observed. During deep sleep (NREM3). signals most closely following this relationship may be observed, while in REM sleep, the connection betweenAtty.Dkt.No. 125141.05018.MGH2025-378electrical activity and hemodynamic response may be less clear. The degree of neurovascular coupling as observed through this timing metric, combined with the sleep stage when the signals were measured, may be indicative of the level of activity of the glymphatic system.
[0080] Referring to FIGS. 10A-10D, example plots illustrating neurovascular coupling during different sleep stages are shown. FIG. 10A illustrates an N3 sleep stage plot 1010 of mean 5-band power, and FIG. 10C illustrates an N3 sleep stage plot 1030 of mean AHbO / HbR. FIG. 10B illustrates a REM sleep stage plot 1020 of mean 5-band power, and FIG. 10D illustrates a REM sleep stage plot 1040 of mean AHbO / HbR. Invasive imaging studies in animals have noted differences in glymphatic function during different sleep stages, with N3 having greater glymphatic activity' than during REM or wakefulness. As illustrated in FIGS.10A-10D, the timing of the changes in delta band EEG power in different sleep stages may have different lags relative to the hemodynamic response, indicating a difference in the degree of neurovascular coupling. The temporal structure of these signals may be indicative of the brain's ability' to drive fluid exchange during sleep and may serve as markers for general glymphatic health. In some embodiments, the glymphatic function analysis engine 206 may analyze the timing relationships between delta band EEG power and hemodynamic responses across different sleep stages to compute the third metric corresponding to neurovascular coupling as described above with respect to operation 530.
[0081] At operation 535, a report is output, which indicates a predicted health of a glymphatic system of the subject based on the first, second, and third metrics. In some embodiments, three metrics may be synthesized into a single prediction to provide an overall assessment of glymphatic function. For example, dysfunction in the glymphatic system may be detected from a reduced value of overall NIRS low frequency power corresponding to the first metric, whether compared to previous nights on a same user, or compared to an average cross-sectional distribution of low frequency power. Moreover, dysfunction may also be detected by a lack of increased low frequency7power as sleep depth increases, corresponding to the second metric. A lack of optical parameter response, such as changes in HbO, HbR, or H2O, to low' frequency EEG power as a function of sleep stage or sleep depth, corresponding to the third metric, may also indicate a dysfunctional glymphatic system. In some aspects, each of the three metrics may be scored equally in determining a user’s glymphatic health score (e.g., a total glymphatic health score can be determined based on an average of the first score corresponding to the first metrix, a second score corresponding to the second metric, and a third score corresponding to a third metric). The report may be generated by the glymphatic function analysis engine 206 and presented via the output 208 of the system 200. By combining measurements of EEG forAtty.Dkt.No. 125141.05018.MGH2025-378electrical activity acquired via the EEG montage 302 of the sensor assembly 300 and nearinfrared spectroscopy (NIRS) measurements of blood volume and CSF (water) volume acquired via the NIRS portion 304 or the optical sensor portion 408, the system 200 may interrogate the glymphatic system during sleep to assess the health and function of the system. In some aspects, the output 208 may provide the report including one or more of the computed metrics along with trend data over multiple sleep sessions, enabling longitudinal tracking of glymphatic health as described with respect to FIG. 2.
[0082] In some embodiments, operations 520, 525, and 530 may be performed in parallel, such that the first metric, the second metric, and the third metric are computed concurrently. In other embodiments, operations 520, 525, and 530 may be performed in various orders. For example, operation 530 may be performed before operation 520. or operation 525 may be performed before operations 520 and 530. The order in which the metrics are computed may depend on computational resources, processing priorities, or other implementation considerations.Example Methods, Experiments, and Embodiments
[0083] The inventors performed certain experiments using the foregoing processes and models described above. The following description provides non-limiting examples and experiments used in those experiments, for testing purposes only. Accordingly, the following description is directed to non-limiting examples provided to give context to the foregoing description. It will be evident that various modifications may be made thereto without departing from the broader spirit and scope of implementations of the disclosure as set forth in the claims.
[0084] In an experimental example, the aims of a project were as follows: Aim 1. Hardware modification: A FlexNIRS device was modified to acquire overnight data at 760,810,850and 970 nm, to separate deoxy-hemoglobin, oxy-hemoglobin, and water concentration changes. Aim 2. Laboratory testing: The GS-FlexNIRS device was tested in young (18-39) and older subjects (60-75) during a sleep cycle in a controlled lab environment. Sleep stages were assessed with co-acquired polysomnography (PSG). Data processing algorithms system hemoglobin and water fluctuations during deep sleep, and investigate age-related reductions in GS activity. Aim 3. At home feasibility: Demonstrate feasibility of conducting overnight GS-FlexNIRS measurements at home in 10 healthy young subjects.
[0085] In the experimental example, pilot studies were conducted to guide the design of a NIRS wearable device and refine data analysis algorithms before incorporating the method into a more extensive clinical study. In some embodiments, a wearable GS monitor may facilitate the evaluation of glymphatic function at the consumer level, longitudinally within the homeAtfy.Dkt.No. 125141.05018.MGH2025-378environment during sleep. In some aspects, monitoring capabilities may be employed for sleep quality assessment, providing insights into the efficacy of therapeutic interventions aimed at enhancing GS function. In certain embodiments, this technology may be configured to identify deviations in GS functions, thereby contributing to health management.
[0086] In the experimental example, preliminary findings, illustrated in FIGS. 11A-11D, demonstrated the capability of NIRS to detect low-frequency cerebral hemoglobin oscillations during deep sleep. In particular, FIGS. 11 A and I IB illustrates example plots 1110, 1120 of fMRI cortical BOLD and CSF signals during wakefulness (FIG. 11A) and sleep (FIG. 11B). FIGS. 11C and 11D illustrate example plots 1130, 1140 of FlexNIRS optical densify signals at 850 nm (volume) recorded from a subject during wake (FIG. 11C) and deep sleep (FIG. 1 ID), as indicated by a sleep tracker wristband. The change in OD oscillations observed during deep sleep closely resemble the low-frequency BOLD oscillations associated with glymphatic activity. These observations aligned with glymphatic-associated, cortical hemoglobin fluctuations previously measured using BOLD functional MRI. The NIRS data presented in FIGS. 11C-11D was acquired utilizing a wearable wireless app-controlled device, FlexNIRS. This device allowed for the measurement of changes in oxy- and deoxy-hemoglobin concentrations ( HbO and HbR ) at high sampling rate and signal-to-noise ratio (SNR). The FlexNIRS enabled the resolution of cardiac, respiratory , and lower frequency hemoglobin oscillations in ecologically valid conditions during overnight sleep. FIGS. 12A-12C illustrate additional example plots 1210. 1220. 1230, respectively, of overnight measurements performed with a 9-wavelength, linear GS-FlexNIRS with sleep staging provided by a smart watch. Plot 1210 demonstrates concentrations of oxy- and deoxy-hemoglobin within normal ranges, as well as normal saturation values with tissue water fraction also within normal ranges. Plot 1220 demonstrates the accelerometer output as a function of the overnight measurement. Plot 1230 shows sleep staging as performed by the smart watch. FIGS. 13A-13C illustrate plots 1310, 1320, and 1330, respectively, of the extracted period of deep sleep from the plots of FIGS.12A-12C. The overnight measurements in FIGS. 13A-13C demonstrate strong fluctuations in the hemoglobin traces, as well as in the tissue water fraction traces. Plot 1310 illustrates changes in HbO versus time, plot 1320 illustrates changes in HbR versus time, and plot 1330 illustrates changes in H2O versus time.
[0087] In the experimental example, the project aimed to enhance the monitoring of GS function with FlexNIRS by incorporating an additional wavelength at 970 nm , centered around a water absorption peak (Aim 1). This addition allowed for detection of low-frequency CSF oscillations alongside hemodynamic oscillations and resolution of level changes in cerebralAtty.Dkt.No. 125141.05018.MGH2025-378water fraction ( H20), corresponding to increases in interstitial and perivascular volume during sleep, thereby offering a more comprehensive understanding of the dynamics of the glymphatic system in humans. NIRS has been used in the past to detect changes in tissue water fraction, and an approach was employed to enable high SNR measurements with a device suitable for ecologically valid sleep. The approach involved the use of 4 wavelengths in a self-calibrated multi-distance geometry, and specialized electronics to enhance SNR at the longer wavelengths. Simulations and preliminary data, illustrated in FIGS. 14A and 14B, respectively, indicated the feasibility of the proposed method. In particular, FIG. 14A illustrates example plots of estimated recovery' of chromophores changes using Monte Carlo simulation of a realistic head geometry'. The noise properties for the current (+970 nm) and the planned GS-FlexNIRS devices. When changing concentration of brain HbO (plot 1410), HbR (plot 1420), H2O (plot 1430) with the selected wavelengths, chromophores concentration changes are recovered with minimal crosstalk. FIG. 14B illustrates data collected at 100 Hz and 3.3 cm separation on the forehead of a volunteer with a modified FlexNIRS using the proposed PDs and 2 LEDS at 980 nm (SMT980D). The GS-FlexNIRS device was evaluated in a controlled laboratory environment using young, healthy subjects (Aim 2). This assessment was conducted alongside wearable polysomnography (PSG), which provides EEG, ECG, respiration rate, EMG, and pulse oximetry7, to characterize sleep stages and validate the correlation between GS activity, deep sleep stages, and slow variation in delta EEG power. Furthermore, the device's capability to detect glymphatic-related changes in Hb and H2O in individuals with different skin tones was demonstrated. In a subsequent phase of Aim 2, 10 older subjects were included to investigate reduction in GS functionality' associated with aging. In Aim 3 the GS-FlexNIRS was evaluated in a real-world scenario by conducting an at-home sleep study to demonstrate the feasibility7and practicality of utilizing the GS-FlexNIRS device outside a laboratory setting.
[0088] In the experimental example, a glymphatic system NIRS device was based on a FlexNIRS prototype (FIG. 4), and optoelectronic components were selected to optimize the device for this application. In particular, a dual-color LED package (SMT760 / 850, Marubeni America Corporation) was replaced by high-power LED packages (4 colors) (EDCC family, Marubeni). The 4-color LEDs were fabricated within independent ceramic packages measuring 1.5 mm X 1.85 mm, and, for the same driving current, provided almost 2 times higher optical power than the SMD dual LEDs. Selecting from the available colors, the selected LEDs were emitting at 760, 810, 850, and 970 nm. These wavelengths were strategically chosen to ensure accurate assessment of HbO, HbRand H20. To discern changes in water concentration, a 970Atty.Dkt.No. 125141.05018.MGH2025-378nm wavelength was utilized, which is close to the 980 nm water peak. Further, including a fourth wavelength around the isosbestic point of hemoglobin (810 nm) enabled a more distinct differentiation between Hb and H20. The hardware and sampling parameters were optimized to compensate for the high tissue absorption at 970 nm. Consequently, the photodetectors (PD) (VEMD5060X01, Vishay Semiconductors) were replaced with PDs featuring enhanced sensitivity and a peak detection shifted to 950 nm (VEMD5080X01).
[0089] Preliminary multilayer Monte Carlo simulations of a realistic head geometry which incorporated the noise properties of selected components indicated that with this wavelengths choice, small brain changes in oxy- deoxy -hemoglobin and water concentration changes could be recovered with minimal crosstalk, and that with the hardware a~3x contrast-to-noise ratio improvement was achieved with respect to the SMT LEDs series and current PDs (FIG. 12A). The simulations suggested this approach improved SNR by ~ 7 dBat 970 nm and increased the sensitivity to cerebral water fraction signal by threefold. Preliminary measurements conducted with a modified FlexNIRS operating at 980 nm (SMT980D) demonstrated the capability to detect cerebral pulsatile and respiratory’ signals at 3.3 cm source-detector separation at this longer wavelength with excellent SNR (FIG. 12B).
[0090] As implemented in the FlexNIRS, a self-calibrating geometry based on 2 sources and 2 detectors placed symmetrically was used to provide two sets of identical long source-detector separations (LS). The symmetric geometry compensated for component variability without need for external calibration and provided quality control metrics. The multi-distance scheme utilized the slopes of intensity' vs distance to quantify chromophores, reducing sensitivity to skin color, and increasing depth sensitivity compared to a single intensity measure. A third PD placed at a short-separation (SS, < 1 cm) enabled the acquisition of superficial scalp signals for subtraction from long source-detector channels, further enhancing depth sensitivity.
[0091] To drive 8 LEDs (4 per source location) the Analog Front End (AFE) integrated circuit (IC) AFE4900 (Texas Instruments) was replaced by an AFE4460. The AFE4460 IC allowed for driving up to 32 independent LEDs with up to 350 mA driving current (the previous system was limited to 200 mA) and sampling 4 PD (2 in parallel). The short-separation and background ambient light were also sampled, leading to an overall number of 15 phases driven by the AFE at 50 Hz sampling rate. Finally, to sustain the higher LED driving current, the battery was replaced with another medical -grade Li-Po with increased charge capacity of 1900 mAh (LP103450JH, Jauch Quartz America. Inc.) and comparable size-factor, maintaining the estimated battery’ life of 8 hours. As implemented, in one example, the GS-FlexNIRS wasAtty.Dkt.No. 125141.05018.MGH2025-378manufactured on a flex printed circuit board (PCB), allowing the hosting of narrow-pitch ICs while offering flexibility to accommodate for the head curvature of the subject and maximize the optical coupling. In some embodiments, the source-detector separation may be 0.8, 2.8, and 3.3 cm and the overall board dimension may be 8 cm X 2.3 cm. A 3-axis accelerometer and gyroscope IC (ADXL344, Analog Devices) was embedded on the PCB to allow tracking subjects movements and reject motion artifacts in the optical data. Finally, a microcontroller (BGM220S, Blue Gecko Bluetooth SiP Module, Silicon Labs) ran the measurement routine: programming the AFE, acquiring the sampled light and motion signals and transmitting data to the external tablet through a Bluetooth low energy' 5.2 communication. Despite the higher number of sources, thanks to the parallel acquisition of the AFE, the higher power of the LEDs, and the higher PD sensitivity in the infrared, the 4-color FlexNIRS when operating at 50 Hz achieved a NEP 7 W / -' Hz and a dynamic range > 80 dB. The device was encapsulated in a low-profde, medical-grade silicone elastomer (Elkem RTV-4420) vacuum-cast case and embedded in a fabric headband. The sensor area had a cutout on the inner side for contact with the skin. Finally, a clip-in socket for the battery was either attached to the headband or routed to the chest of the subject and attached to the PSG system. Magnetic pogo-pin connectors were used to allow for easy battery' replacement. The weight of the entire assembly was around 2 — 3 ounces ( ~ 60 — 80 grams). In the experimental example, the circuit design and manufacturing were finalized, and firmware programming, packaging, and characterization were completed. Meanwhile the Android app was modified to control and display' the 4-wavelength data, estimate water fraction changes in addition to hemoglobin oxygenation and concentration changes, and provide additional data quality’ feedback at the additional wavelengths.
[0092] Data pre-processing: Raw data may be preprocessed by removing periods with excessive motion artifacts as detected by the built-in accelerometer. Changes in head position may be flagged in the data. For the fluctuation analysis optical, densities (ODs) may be bandpass filtered (0.01 — 10 Hz)to extract relevant oscillations frequencies. For slow water level changes, after ambient light subtraction, an average OD for each cardiac pulse may be computed to remove high frequency signals. In both cases, the multi-wavelength multi-distance self-calibrated approach described herein may be used to estimate HbO, HbR,and H2Ochanges. Chromophore concentration estimates may be computed in a spectrally aware manner, considering the linewidth of the LEDs and the responsivity of the PDs.Atty.Dkt.No. 125141.05018.MGH2025-378
[0093] Increase in GS fluctuation's amplitude during deep sleep: To assess the contributions at different frequencies a sleep stage specific analysis may be performed, following established fNIRS approaches for analyzing resting state network data. Both OD and concentration data may be considered. Data may be separated into 5-minute windows, and a generalized linear model (GLM) framework may be used to remove correlated changes in large and short separation signals data. SS signals may be first band pass filtered into three distinct bands representing the cardiac pulsation ( 0.6 Hz — 10 Hz), the respiratory fluctuation ( 0.15 Hz — 0.6 Hz), and low frequency oscillation (0.01 Hz — 0.15 Hz)representative of glymphatic flow.
[0094] An example of a full night sleep analyzed with this method can be seen in FIG. 15. In particular FIG. 15 illustrates an example plot 1510 a multi-taper spectrogram of the long-separation FlexNIRS optical density (OD at 850 nm, after short-separation regression) during sleep. The cardiac, respiratory, and glymphatic frequencies can be seen to vary in both amplitude and frequency throughout the night. Example plot 1520 illustrates a time domain representation of the glymphatic frequency band and example plots 1530, 1540, and 1550 illustrate extracted segments showing examples of lower amplitude fluctuations, higher amplitude fluctuations, and a transition from low to high. Data was acquired with a dual-color FlexNIRS on a young subject. The multi -taper spectrogram computed from the 850 nm ADD regressed signal contains cardiac, respiratory , and low-frequency bands that can be seen to vary in both amplitude and frequency throughout the night. In the spectrogram, the low frequency component (< 0.1 Hz) is the most prominent earlier in the night with increases in the respiratory band (~ 0.2 Hz)becoming apparent later in the night. The amplitude of the low frequency oscillations fluctuate throughout the night. In these preliminary data a wristband sleep tracker was used to assess sleep stages. In the proposed project. EEG signals from the PSG may be used to demonstrate that the increases in the low-frequency band occur during deep sleep stages.
[0095] To demonstrate increases in amplitude of GS hemoglobin and water low-frequency fluctuations during deep sleep, the PSG time courses information may be added into spectrograms and sleep stage specific frequency power spectra may be computed. One-sided paired t-tests may be utilized to demonstrate a higher signal power in the low frequency bands during deep sleep compared to wakefulness or REM. Assuming a standard deviation of 3, to detect a difference of 1.5 (effect size 0.5, ctO.05) with a sample size of 30, the power may be 83%.Atty.Dkt.No. 125141.05018.MGH2025-378
[0096] Relationship with neuronal activity: To examine the relationship between cerebrovascular driven oscillations and neuronal activity, a sleep stimulus driven analysis may be performed following standard fNIRS evoked response data analysis methods. EEG derived relevant sleep features (infraslow oscillation in EEG delta power, sleep spindles, etc.) may be used as stimulus triggers, and a block average GLM approach may be adapted for analysis. For each subject and stimulus type, a response function may be simultaneously fit using GLM SS regression. Aggregated responses may be derived from the individual stimulus events, and the extracted cerebral response may be compared between stimuli.
[0097] Water content changes during sleep: Using the filtered data, slow cerebral water fraction levels across sleep stages may be estimated. As shown in small animals, interstitial cerebral water content increases by ~ 10%between sleep and wake, which may increase the optical absorption coefficient of the brain at 970 nm by approximately the same factor. To investigate the influence of sleep state on cerebral water content, relative changes in water fraction may be compared between sleep and wake and between different sleep stages.
[0098] GS function decrease with age: Comparisons of the length of low-frequency oscillation periods, normalized by the hours of sleep, may be conducted between younger and older subjects. One-sided t-tests may be used to examine whether age influences the amount of low-frequency oscillations during sleep. While this is an exploratory aim, if the effect size is large (0.8), with a sample size of 10 old and 30 young subjects the power to detect a difference may be 70%.
[0099] Skin tone effect: To explore the potential influence of skin pigmentation on the detection of low-frequency GS oscillations, grouped analyses based on skin color may be conducted. These analyses may compare the relative changes of low-frequency oscillations during stable wake, stable sleep, and the difference between sleep and wake. While lower SNR in the darker skin group may be anticipated, signal degradation at 970 nm may not be expected, as melanin absorption is significantly reduced at longer wavelengths. Similar relative changes in GS low-frequency oscillations in the young healthy population regardless of skin tone may be anticipated, as the FlexNIRS employs a multi-distance approach to quantify chromophores that may be insensitive to an absorbing thin superficial layer.
[0100] Because of intensity changes due to motion artifacts and head position changes in some individuals during a night of sleep, quantification of overnight changes in water fraction levels based purely on intensity may not be feasible in some embodiments. Concentration change estimates using the multi-distance self-calibrating geometry method may be less sensitive than those computed with a single distance and without the self-calibrating geometry.Atty.Dkt.No. 125141.05018.MGH2025-378Nonetheless, efforts may be made to minimize these artifacts. To prevent probe movement, medical-grade adhesive may be used to secure the GS-FlexNIRS to the skin as needed. Additionally, to minimize head turning during sleep, in addition to ensuring a comfortable sleep environment, subjects may be encouraged to bring their own favorite firm pillow and to sleep on their backs. Moreover, measurement sessions impacted by restless sleep or an inability' to sleep for at least 4 hours may be excluded from the analysis. Additional subjects may be enrolled as needed to maintain an adequate sample size. If the 12 EEG electrodes montage of the PSG is insufficient for the sleep stimulus driven analysis, 256-channel geodesic nets and theNA410 amplifier (Electrical Geodesics, Inc., Eugene, OR USA) may be used.
Claims
Atty.Dkt.No. 125141.05018.MGH2025-378CLAIMSWHAT IS CLAIMED IS:
1. A system for evaluating brain health of a subject, the system comprising: a sensor assembly comprising:one or more electroencephalography (EEG) sensors; anda plurality of near-infrared spectroscopy (NIRS) sensors including a light source and a photodetector;a control unit in electrical communication with the sensor assembly, the control unit configured to:acquire, via the sensor assembly, EEG data from the EEG sensors and NIRS data from the NIRS sensors, the EEG data and NIRS data obtained during a sleeping state of the subject;process the EEG data and NIRS data to identify a first plurality of oscillations in the EEG data and a second plurality of oscillations in the NIRS data;determine a metric based on the first plurality of oscillations and the second plurality of oscillations; andoutput a report to a user, the report indicating a predicted brain health of the subject based on the metric.
2. The system of claim 1, wherein the metric is determined based on an area under a curve of the second plurality of oscillations, wherein the metric corresponds to a predicted sleep efficacy.
3. The system of claim 1, wherein the metric is determined by comparing a spectral power of the first plurality of oscillations and the second plurality of oscillations at various sleep stages, wherein the metric corresponds to an entrainment of low-frequency neural activity into hemodynamic signals.
4. The system of claim 3, wherein the spectral power corresponds to frequency bands of approximately 0.01 Hz to 0.15 Hz.Atty.Dkt.No. 125141.05018.MGH2025-3785. The system of claim 1, wherein the metric is determined based on a timing delay between the first plurality of oscillations and the second plurality of oscillations, wherein the metric corresponds to neurovascular coupling.
6. The system of claim 5, wherein the timing delay is between 4 seconds and 6 seconds between a peak of neural activity and a peak of a hemodynamic response.
7. The system of claim 1, wherein the control unit is further configured to: determine a first metric based on an area under a curve of the second plurality of oscillations, wherein the first metric corresponds to a predicted sleep efficacy ;determine a second metric by comparing a spectral power of the first plurality of oscillations and the second plurality of oscillations at various sleep stages, wherein the second metric corresponds to an entrainment of low-frequency neural activity into hemodynamic signals; anddetermine a third metric based on a timing delay between the first plurality of oscillations and the second plurality of oscillations, wherein the third metric corresponds to neurovascular coupling.
8. The system of claim 1, wherein the sensor assembly is wearable.
9. The system of claim 1, wherein the first plurality’ of oscillations comprises low frequency hemodynamic oscillations driven by infraslow oscillations of approximately 0.05 Hz of delta EEG pow er.
10. The system of claim 1, wherein the control unit is further configured to: acquire, via the plurality of NIRS sensors, a plurality' of w avelengths around a water absorption peak; andidentify cerebral water fraction changes from the plurality of wavelengths.
11. A method for evaluating brain health of a subject, the method comprising: acquiring, via a sensor assembly comprising one or more electroencephalography (EEG) sensors and a plurality of near-infrared spectroscopy (NIRS) sensors, EEG data and NIRS data during a sleeping state of the subject;Atty.Dkt.No. 125141.05018.MGH2025-378pre-processing the EEG data and NIRS data to identify a first plurality of oscillations in the EEG data and a second plurality of oscillations in the NIRS data;determining a metric based on the first plurality of oscillations and the second plurality of oscillations; andoutputting a report to a user, the report indicating a predicted brain health of the subject based on the metric.
12. The method of claim 11, wherein the metric is determined based on an area under a curve of the second plurality of oscillations, wherein the metric corresponds to a predicted sleep efficacy.
13. The method of claim 11, wherein the metric is determined by comparing a spectral power of the first plurality of oscillations and the second plurality of oscillations at various sleep stages, wherein the metric corresponds to an entrainment of low-frequency neural activity into hemodynamic signals.
14. The method of claim 13, wherein the spectral power corresponds to frequency bands of approximately 0.01 Hz to 0.15 Hz.
15. The method of claim 11. wherein the metric is determined based on a timing delay between the first plurality of oscillations and the second plurality of oscillations, wherein the metric corresponds to neurovascular coupling.
16. The method of claim 15, wherein the timing delay is between 4 seconds and 6 seconds between a peak of neural activity and a peak of a hemodynamic response.
17. The method of claim 11, further comprising:determining a first metric based on an area under a curve of the second plurality of oscillations, wherein the first metric corresponds to a predicted sleep efficacy;determining a second metric by comparing a spectral power of the first plurality of oscillations and the second plurality of oscillations at various sleep stages, wherein the second metric corresponds to an entrainment of low-frequency neural activity into hemodynamic signals; andAtty.Dkt.No. 125141.05018.MGH2025-378determining a third metric based on a timing delay between the first plurality of oscillations and the second plurality’ of oscillations, wherein the third metric corresponds to neurovascular coupling.
18. The method of claim 11 , wherein the sensor assembly is wearable.19.The method of claim 11, wherein the second plurality of oscillations comprises low frequency hemodynamic oscillations driven by infraslow oscillations of approximately 0.05 Hz of delta EEG power.
20. The method of claim 11 , further comprising:acquiring, via the plurality of NIRS sensors, a plurality of wavelengths around a water absorption peak; andidentifying cerebral water fraction changes from the plurality' of wavelengths.
